Social Security Fully Insured

"Social Security Fully Insured" refers to a person's eligibility for certain Social Security benefits based on their work history and Social Security taxes paid. Here are the key features of beingSocial Security Fully Insured:

 

·      Work History: To be Social Security FullyInsured, a person must have worked and paid Social Security taxes for a certain amount of time, earning enough credits to qualify for benefits.

 

·      Credits: Social Security credits are earned based on a person's earnings from work covered by Social Security. A person can earn up to four credits per year, and the number of credits they need to beSocial Security Fully Insured depends on their age at the time they become eligible for benefits.

 

·      Eligibility for Benefits: Being Social SecurityFully Insured means a person is eligible for certain Social Security benefits, including retirement, disability, and survivor benefits.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.